Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378171 | 0.83 | LMNA (0.60) | LMNANPC1KMT2ARAB9A | |
| SCHEMBL30609047 | 0.79 | TRPM8 (0.40) | HPGDLMNAPDE4DKMT2ARAB9A | |
| SCHEMBL10612361 | 0.79 | COXFA4 (0.43) | HPGDLMNAPDE4DOPRM1MALT1 | |
| SCHEMBL11223734 | 0.77 | IDO1 (0.39) | HPGDLMNAPDE4DKMT2ARAB9A | |
| SCHEMBL9749197 | 0.76 | SSTR5 (0.37) | HPGDLMNADRD2DRD3 | |
| SCHEMBL27561930 | 0.76 | LMNA (0.36) | HPGDLMNAPDE4DKMT2ARAB9A | |
| SCHEMBL15075059 | 0.76 | HTR2C (0.47) | HPGDLMNAKMT2ARAB9ADRD2 | |
| SCHEMBL6391861 | 0.75 | HPGD (0.47) | HPGDPDE4DKMT2AOPRM1 | |
| SCHEMBL10800882 | 0.75 | KMT2A (0.40) | LMNANPC1KMT2ARAB9ADRD2 | |
| SCHEMBL7321223 | 0.74 | HPGD (0.39) | HPGDOPRM1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023246854-A1 | CRYSTAL OF BORATE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | 瑞石生物医药有限公司 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023246858-A1 | PHARMACEUTICAL SALT OF BORATE DERIVATIVE, AND CRYSTALLIZATION FORM AND USE THEREOF | 瑞石生物医药有限公司 | 2023-12-28 | — | — | WO | disclosed |
| CN-103980235-A | GPR120 receptor agonists and uses thereof | CYMABAY THERAPEUTICS INC | 2014-08-13 | — | — | CN | disclosed |
| CN-102307860-B | GPR120 receptor agonists and uses thereof | METABOLEX INC | 2014-07-02 | — | — | CN | disclosed |
| US-20120145974-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| CN-102307860-A | GPR120 receptor agonists and uses thereof | METABOLEX INC | 2012-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145974-A1 | CHROMENE COMPOUND | CRY2, CYP2J2, NR0B2 | HPGD 909/4885LMNA 2468/4885PDE4D 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.